NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.
{iframe}http://markets.businessinsider.com/news/stocks/NexImmune-Raises-23-Million-to-Advance-Endogenous-Cellular-ImmunoTherapy-into-Clinical-Development-1012405766{/iframe}